Novo Nordisk Buys Hypertension Drug Ocedurenone For $1.3 Billion—Expanding Ozempic Maker’s Arsenal
The Danish firm said the drug has “best-in-class potential” for treating uncontrolled hypertension.
The Danish firm said the drug has “best-in-class potential” for treating uncontrolled hypertension.